Spironolactone: An anti-androgenic and anti-hypertensive drug that may provide protection against the novel Coronavirus (SARS-CoV-2) induced acute respiratory distress syndrome (ARDS) in COVID-19.

Authors: Cadegiani FA, Wambier CG, Goren A

PMID: 32850920 PMCID: PMC7399048 DOI: 10.3389/fmed.2020.00453

Abstract

At the onset of the COVID-19 pandemic, mortality following infection of severe acute respiratory coronavirus (SARS-CoV-2) was thought to be solely associated with aging and pre-existing conditions; however, as the pandemic ensued, several large scale epidemiological observations eluded to additional atypical risk factors, particularly hypertension, obesity, and male gender.

Keywords: Spironolactone, Anti-androgenic, Anti-hypertensive, ARDS, SARS-CoV2, COVID-19

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399048/#:~:text=Since%20spironolactone%20is%20a%20long,can%20decrease%20viral%20priming%20through
Archive: https://archive.is/3xk18